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Purpose of the study
Eradicating cHCV is necessary for the subsequent man-
agement of patients with HIV and every HIV/HCV co-
infected patient should be considered for treatment. We
describe differences between cHCV mono-infected and
cHCV/HIV co-infected patients in baseline factors and
outcome of cHCV-treatment with peginterferon alfa 2a
+ RBV in the worldwide largest cHCV cohort.
Methods
Noninterventional prospective multicenter German
cohort, started January 2008 and still recruiting. Interim
analysis of cHCV patients, stratified for cHCV mono-
infection and cHCV/HIV co-infection. The results are
based on a cross-sectional analysis of all available data
in April 2010.
Results
This interim analysis included 5.390 patients, who
received HCV-treatment. 397 were cHCV/HIV co-
infected (CI) and 4.993 cHCV mono-infected (MI).
Main baseline- characteristics: 85.9% were GT1/4/5/6
patients in the CI-Group and 63.4% in the MI-Group,
age was 41.0 (CI), 42.0 (MI) yrs, 89.7 (CI), 62.9 (MI)%
were male, BMI was 22.8 (CI), 24.9 (MI) kg/m
2,n a ï v e /
relapse/non-responder/re-infection: 86.4/3.8/4.5/5.3(CI),
88.0/6.1/5.3/0.6 (MI) %, source of infection (>1 answer
possible): iv drug use 25.2(CI), 44.9(MI) %, sexual trans-
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unknown 13.1(CI), 33.0 (MI)%. 86.4 % of the co-infected
patients received antiretroviral HIV-treatment (ART),
66.2 % of them had an HIV-RNA level below 50 copies/
mL, median CD4-cells/µ count was 502. From those
patients who finished treatment, 52.9% of the CI-Group
and 67.7% of the MI-Group completed the planned
course. Reasons for discontinuation (>1 answer possible)
were non-response (59.3% in CI, 45.5 % in MI) and
patient request (24.7% in CI, 14.5% in MI). Other rea-
sons were tolerability (11.1% in CI, 12.0% in MI) and
compliance issues (12.3% in CI, 10.5% in MI).Treatment
response rates, stratified by genotypes, were already
available regarding RVR and EVR (see Figure 1)
Conclusions
In this preliminary analysis HCV/HIV co-infected
patients seemed to respond similar according to RVR
and EVR in GT1/4/5/6 as HCV-mono infected patients
on HCV-treatment. Treatment discontinuation due to
non-response and patient request was much more com-
mon in the co-infected group. Other reasons for discon-
tinuation like tolerability and compliance are equal in
both arms.A more detailed analysis, in particular the
influence of the HIV-ART on HCV-therapy outcome,
may help interpreting these data. An updated analysis
will be presented.
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